Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patientsAnnamaria Ruzzo, Mauro Magnani, Francesco Graziano et al.|British Journal of Cancer|2017Cited by 68
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic SettingDaniele Generali, Gabriella Mariani, S. Romito et al.|The Oncologist|2017Cited by 11